423 related articles for article (PubMed ID: 27349252)
41. New algorithm for OHSS prevention.
Papanikolaou EG; Humaidan P; Polyzos N; Kalantaridou S; Kol S; Benadiva C; Tournaye H; Tarlatzis B
Reprod Biol Endocrinol; 2011 Nov; 9():147. PubMed ID: 22054506
[TBL] [Abstract][Full Text] [Related]
42. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
[TBL] [Abstract][Full Text] [Related]
43. GnRH agonist ovulation trigger and hCG-based, progesterone-free luteal support: a proof of concept study.
Kol S; Humaidan P; Itskovitz-Eldor J
Hum Reprod; 2011 Oct; 26(10):2874-7. PubMed ID: 21784738
[TBL] [Abstract][Full Text] [Related]
44. Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial.
Sismanoglu A; Tekin HI; Erden HF; Ciray NH; Ulug U; Bahceci M
J Assist Reprod Genet; 2009 May; 26(5):251-6. PubMed ID: 19629674
[TBL] [Abstract][Full Text] [Related]
45. Reproductive outcomes of dual trigger therapy with GnRH agonist and hCG versus hCG trigger in women with diminished ovarian reserve: a retrospective study.
Chen K; Zhang C; Chen L; Zhao Y; Li H
Reprod Biol Endocrinol; 2024 Apr; 22(1):35. PubMed ID: 38566172
[TBL] [Abstract][Full Text] [Related]
46. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
[TBL] [Abstract][Full Text] [Related]
47. Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case-control study.
Lewit N; Kol S; Manor D; Itskovitz-Eldor J
Hum Reprod; 1996 Jul; 11(7):1399-402. PubMed ID: 8671474
[TBL] [Abstract][Full Text] [Related]
48. Ovarian hyperstimulation syndrome prevention strategies: use of gonadotropin-releasing hormone antagonists.
Griesinger G
Semin Reprod Med; 2010 Nov; 28(6):493-9. PubMed ID: 21082508
[TBL] [Abstract][Full Text] [Related]
49. GnRH agonist triggering: recent developments.
Kol S; Humaidan P
Reprod Biomed Online; 2013 Mar; 26(3):226-30. PubMed ID: 23337420
[TBL] [Abstract][Full Text] [Related]
50. Use of gonadotrophin-releasing hormone agonists to trigger ovulation.
Tay CC
Hum Fertil (Camb); 2002 Feb; 5(1):G35-7; discussion G38-9, G41-8. PubMed ID: 11939159
[TBL] [Abstract][Full Text] [Related]
51. [GnRH agonist triggering in IVF and luteal phase support in women at risk of ovarian hyperstimulation syndrome].
Guivarc'h-Levêque A; Jaffré F; Homer L; Moy L; Priou G; Colleu D; Denis I; Arvis P
Gynecol Obstet Fertil; 2013 Sep; 41(9):511-4. PubMed ID: 23972925
[TBL] [Abstract][Full Text] [Related]
52. Agonist trigger: what is the best approach? Agonist trigger and low dose hCG.
Humaidan P
Fertil Steril; 2012 Mar; 97(3):529-30. PubMed ID: 22154368
[TBL] [Abstract][Full Text] [Related]
53. Relationship between human chorionic gonadotropin serum levels and the risk of ovarian hyperstimulation syndrome.
Johnson MD; Williams SL; Seager CK; Liu JH; Barker NM; Hurd WW
Gynecol Endocrinol; 2014 Apr; 30(4):294-7. PubMed ID: 24455971
[TBL] [Abstract][Full Text] [Related]
54. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels.
Manzanares MA; Gómez-Palomares JL; Ricciarelli E; Hernández ER
Fertil Steril; 2010 Mar; 93(4):1215-9. PubMed ID: 19200978
[TBL] [Abstract][Full Text] [Related]
55. Comparison between hCG and GnRH Agonist for Ovulation Trigger in GnRH Antagonist In-Vitro Fertilization Cycles in a Tertiary Hospital in Malaysia: An observational study.
Aziz NA; Ibrahim A; Ramli R; Yaacob N; Rahman SNA; Ismail EHE; Omar AA
JBRA Assist Reprod; 2024 Feb; 28(1):21-26. PubMed ID: 38224580
[TBL] [Abstract][Full Text] [Related]
56. Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction.
Araujo E; Bernardini L; Frederick JL; Asch RH; Balmaceda JP
J Assist Reprod Genet; 1994 Feb; 11(2):74-8. PubMed ID: 7819706
[TBL] [Abstract][Full Text] [Related]
57. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
58. [Research on the protocol of limited ovarian stimulation to prevent ovarian hyperstimulation syndrome].
Zhu YM; Gao HJ; He RH; Huang HF
Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):740-4. PubMed ID: 17327030
[TBL] [Abstract][Full Text] [Related]
59. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
[TBL] [Abstract][Full Text] [Related]
60. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
